Identification and validation of a novel cuproptosis signature for stratifying different prognostic, immune, metabolic, and therapeutic landscapes in pancreatic adenocarcinoma

CONCLUSIONS: The novel CR risk signature contributed to the risk stratification of PAAD patients. Cuproptosis regulatory genes, well represented by LIPT1, provided new insights into PAAD treatment and assessment.PMID:38497885 | DOI:10.26355/eurrev_202403_35617

Source: Pharmacological Reviews - March 18, 2024 Category: Drugs & Pharmacology Authors: X Yan W Zheng F-S Xu H-L Chang Y Zhang Z-Y Zhang Y-H Zhang Source Type: research